Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy
Cilengitide (EMD 121974) (IND# 59073) in Recurrent or Progressive and Refractory Childhood High-Grade Glioma
Status: Enrolling
Updated:  12/31/1969
Seattle Children's Hospital
mi
from
Seattle, WA
Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy
Cilengitide (EMD 121974) (IND# 59073) in Recurrent or Progressive and Refractory Childhood High-Grade Glioma
Status: Enrolling
Updated: 12/31/1969
Seattle Children's Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy
Cilengitide (EMD 121974) (IND# 59073) in Recurrent or Progressive and Refractory Childhood High-Grade Glioma
Status: Enrolling
Updated:  12/31/1969
Midwest Children's Cancer Center
mi
from
Milwaukee, WI
Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy
Cilengitide (EMD 121974) (IND# 59073) in Recurrent or Progressive and Refractory Childhood High-Grade Glioma
Status: Enrolling
Updated: 12/31/1969
Midwest Children's Cancer Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy
Cilengitide (EMD 121974) (IND# 59073) in Recurrent or Progressive and Refractory Childhood High-Grade Glioma
Status: Enrolling
Updated:  12/31/1969
CancerCare Manitoba
mi
from
Winnipeg,
Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy
Cilengitide (EMD 121974) (IND# 59073) in Recurrent or Progressive and Refractory Childhood High-Grade Glioma
Status: Enrolling
Updated: 12/31/1969
CancerCare Manitoba
mi
from
Winnipeg,
Click here to add this to my saved trials
Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients With Newly Diagnosed WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma
A Phase 1 Trial of CMV RNA-Pulsed Dendritic Cells With Tetanus-Diphtheria Toxoid Vaccine in Pediatric Patients With Newly Diagnosed WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma
Status: Enrolling
Updated:  12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients With Newly Diagnosed WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma
A Phase 1 Trial of CMV RNA-Pulsed Dendritic Cells With Tetanus-Diphtheria Toxoid Vaccine in Pediatric Patients With Newly Diagnosed WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors
A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy
Status: Enrolling
Updated:  12/31/1969
CCOP - Western Regional, Arizona
mi
from
Phoenix, AZ
Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors
A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy
Status: Enrolling
Updated: 12/31/1969
CCOP - Western Regional, Arizona
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors
A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy
Status: Enrolling
Updated:  12/31/1969
CCOP - Central Illinois
mi
from
Decatur, IL
Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors
A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy
Status: Enrolling
Updated: 12/31/1969
CCOP - Central Illinois
mi
from
Decatur, IL
Click here to add this to my saved trials
Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors
A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy
Status: Enrolling
Updated:  12/31/1969
MBCCOP - LSU Health Sciences Center
mi
from
New Orleans, LA
Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors
A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy
Status: Enrolling
Updated: 12/31/1969
MBCCOP - LSU Health Sciences Center
mi
from
New Orleans, LA
Click here to add this to my saved trials
Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors
A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy
Status: Enrolling
Updated:  12/31/1969
CCOP - Southeast Cancer Control Consortium
mi
from
Goldsboro, NC
Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors
A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy
Status: Enrolling
Updated: 12/31/1969
CCOP - Southeast Cancer Control Consortium
mi
from
Goldsboro, NC
Click here to add this to my saved trials
Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors
A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy
Status: Enrolling
Updated:  12/31/1969
Comprehensive Cancer Center of Wake Forest University
mi
from
Winston-Salem, NC
Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors
A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy
Status: Enrolling
Updated: 12/31/1969
Comprehensive Cancer Center of Wake Forest University
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors
A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy
Status: Enrolling
Updated:  12/31/1969
CCOP - Columbus
mi
from
Columbus, OH
Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors
A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy
Status: Enrolling
Updated: 12/31/1969
CCOP - Columbus
mi
from
Columbus, OH
Click here to add this to my saved trials
Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors
A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy
Status: Enrolling
Updated:  12/31/1969
CCOP - Upstate Carolina
mi
from
Spartanburg, SC
Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors
A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy
Status: Enrolling
Updated: 12/31/1969
CCOP - Upstate Carolina
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Neurobehavioral Functioning in Pediatric Brain Tumor Patients After Proton Beam Radiation Treatment
Neurobehavioral Functioning and Utilization of Special Education Services in Pediatric Brain and CNS Tumor Patients After Proton Radiation Treatment: A Longitudinal Study
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Neurobehavioral Functioning in Pediatric Brain Tumor Patients After Proton Beam Radiation Treatment
Neurobehavioral Functioning and Utilization of Special Education Services in Pediatric Brain and CNS Tumor Patients After Proton Radiation Treatment: A Longitudinal Study
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery
A Phase 0 First-In-Human Study Using NU-0129: A Spherical Nucleic Acid (SNA) Gold Nanoparticle Targeting BCL2L12 in Recurrent Glioblastoma Multiforme or Gliosarcoma Patients
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery
A Phase 0 First-In-Human Study Using NU-0129: A Spherical Nucleic Acid (SNA) Gold Nanoparticle Targeting BCL2L12 in Recurrent Glioblastoma Multiforme or Gliosarcoma Patients
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Donepezil in Treating Young Patients With Primary Brain Tumors Previously Treated With Radiation Therapy to the Brain
A Pilot Study of Donepezil Hydrochloride in Pediatric Brain Tumor Survivors After Cranial Irradiation
Status: Enrolling
Updated:  12/31/1969
Tufts-NEMC Cancer Center
mi
from
Boston, MA
Donepezil in Treating Young Patients With Primary Brain Tumors Previously Treated With Radiation Therapy to the Brain
A Pilot Study of Donepezil Hydrochloride in Pediatric Brain Tumor Survivors After Cranial Irradiation
Status: Enrolling
Updated: 12/31/1969
Tufts-NEMC Cancer Center
mi
from
Boston, MA
Click here to add this to my saved trials
Donepezil in Treating Young Patients With Primary Brain Tumors Previously Treated With Radiation Therapy to the Brain
A Pilot Study of Donepezil Hydrochloride in Pediatric Brain Tumor Survivors After Cranial Irradiation
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Donepezil in Treating Young Patients With Primary Brain Tumors Previously Treated With Radiation Therapy to the Brain
A Pilot Study of Donepezil Hydrochloride in Pediatric Brain Tumor Survivors After Cranial Irradiation
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Mobile Infirmary Medical Center
mi
from
Mobile, AL
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Mobile Infirmary Medical Center
mi
from
Mobile, AL
Click here to add this to my saved trials
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Fairbanks Memorial Hospital
mi
from
Fairbanks, AK
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Fairbanks Memorial Hospital
mi
from
Fairbanks, AK
Click here to add this to my saved trials
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Arizona Oncology Services Foundation
mi
from
Scottsdale, AZ
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Arizona Oncology Services Foundation
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Alta Bates Summit Medical Center-Herrick Campus
mi
from
Berkeley, CA
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Alta Bates Summit Medical Center-Herrick Campus
mi
from
Berkeley, CA
Click here to add this to my saved trials
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Mills-Peninsula Medical Center
mi
from
Burlingame, CA
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Mills-Peninsula Medical Center
mi
from
Burlingame, CA
Click here to add this to my saved trials
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
John Muir Medical Center - Concord Campus
mi
from
Concord, CA
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
John Muir Medical Center - Concord Campus
mi
from
Concord, CA
Click here to add this to my saved trials
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Marin General Hospital
mi
from
Greenbrae, CA
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Marin General Hospital
mi
from
Greenbrae, CA
Click here to add this to my saved trials
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Sutter Cancer Research Consortium
mi
from
Novato, CA
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Sutter Cancer Research Consortium
mi
from
Novato, CA
Click here to add this to my saved trials
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
California Pacific Medical Center-Pacific Campus
mi
from
San Francisco, CA
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
California Pacific Medical Center-Pacific Campus
mi
from
San Francisco, CA
Click here to add this to my saved trials
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Sutter Solano Medical Center/Cancer Center
mi
from
Vallejo, CA
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Sutter Solano Medical Center/Cancer Center
mi
from
Vallejo, CA
Click here to add this to my saved trials
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
John Muir Medical Center-Walnut Creek
mi
from
Walnut Creek, CA
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
John Muir Medical Center-Walnut Creek
mi
from
Walnut Creek, CA
Click here to add this to my saved trials
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Yale University
mi
from
New Haven, CT
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Boca Raton Regional Hospital
mi
from
Boca Raton, FL
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Boca Raton Regional Hospital
mi
from
Boca Raton, FL
Click here to add this to my saved trials
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
University of Florida Health Science Center ?? Gainesville
mi
from
Gainesville, FL
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
University of Florida Health Science Center ?? Gainesville
mi
from
Gainesville, FL
Click here to add this to my saved trials
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Saint Luke's Mountain States Tumor Institute
mi
from
Boise, ID
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Saint Luke's Mountain States Tumor Institute
mi
from
Boise, ID
Click here to add this to my saved trials
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Saint Vincent Anderson Regional Hospital/Cancer Center
mi
from
Anderson, IN
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Saint Vincent Anderson Regional Hospital/Cancer Center
mi
from
Anderson, IN
Click here to add this to my saved trials
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Franciscan Saint Francis Health-Beech Grove
mi
from
Beech Grove, IN
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Franciscan Saint Francis Health-Beech Grove
mi
from
Beech Grove, IN
Click here to add this to my saved trials
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
IU Health Methodist Hospital
mi
from
Indianapolis, IN
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
IU Health Methodist Hospital
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Reid Health
mi
from
Richmond, IN
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Reid Health
mi
from
Richmond, IN
Click here to add this to my saved trials
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
University of Iowa - Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
University of Iowa - Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Click here to add this to my saved trials
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Anne Arundel Medical Center
mi
from
Annapolis, MD
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Anne Arundel Medical Center
mi
from
Annapolis, MD
Click here to add this to my saved trials
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Henry Ford Hospital
mi
from
Detroit, MI
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Borgess Medical Center
mi
from
Kalamazoo, MI
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Borgess Medical Center
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Bronson Methodist Hospital
mi
from
Kalamazoo, MI
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Bronson Methodist Hospital
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
West Michigan Cancer Center
mi
from
Kalamazoo, MI
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
West Michigan Cancer Center
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
William Beaumont Hospital-Royal Oak
mi
from
Royal Oak, MI
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
William Beaumont Hospital-Royal Oak
mi
from
Royal Oak, MI
Click here to add this to my saved trials
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Fairview Ridges Hospital
mi
from
Burnsville, MN
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Fairview Ridges Hospital
mi
from
Burnsville, MN
Click here to add this to my saved trials
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Mercy Hospital
mi
from
Coon Rapids, MN
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Mercy Hospital
mi
from
Coon Rapids, MN
Click here to add this to my saved trials
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Fairview Southdale Hospital
mi
from
Edina, MN
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Fairview Southdale Hospital
mi
from
Edina, MN
Click here to add this to my saved trials
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Unity Hospital
mi
from
Fridley, MN
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Unity Hospital
mi
from
Fridley, MN
Click here to add this to my saved trials
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Minnesota Oncology Hematology PA-Maplewood
mi
from
Maplewood, MN
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Minnesota Oncology Hematology PA-Maplewood
mi
from
Maplewood, MN
Click here to add this to my saved trials
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Abbott Northwestern Hospital
mi
from
Minneapolis, MN
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Abbott Northwestern Hospital
mi
from
Minneapolis, MN
Click here to add this to my saved trials